v3.26.1
Condensed Balance Sheets - USD ($)
Dec. 31, 2025
Dec. 31, 2024
Current liabilities    
Accrued expenses $ 659  
TOTAL LIABILITIES 659  
Commitments and Contingencies  
SHAREHOLDERS' DEFICIT    
Additional paid-in capital 10  
Accumulated deficit (659)  
TOTAL SHAREHOLDERS' DEFICIT (659)  
Archimedes Tech SPAC Partners II Co    
Current assets    
Cash 1,362,766  
Prepaid expenses 111,403  
Total current assets 1,474,169  
Deferred offering costs   $ 429,691
Prepaid insurance 9,896  
Cash held in Trust Account 239,860,969 0
TOTAL ASSETS 241,345,034 429,691
Current liabilities    
Accrued expenses 61,277 23,000
Accrued offering costs 75,000 268,358
Due to related party 1,239 0
Total current liabilities 137,516 483,391
Deferred underwriting fee payable 8,050,000  
TOTAL LIABILITIES 8,187,516 483,391
Commitments and Contingencies
Ordinary shares subject to possible redemption, 23,000,000 shares at redemption value of $10.43 per share as of December 31, 2025 and none at December 31, 2024 239,860,969  
SHAREHOLDERS' DEFICIT    
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding
Ordinary shares, $0.0001 par value; 400,000,000 shares authorized; 6,590,000 and 5,750,000 shares issued and outstanding (excluding 23,000,000 and 0 shares subject to possible redemption) as of December 31, 2025 and 2024, respectively 659 575
Additional paid-in capital   24,425
Accumulated deficit (6,704,110) (78,700)
TOTAL SHAREHOLDERS' DEFICIT (6,703,451) (53,700)
TOTAL LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION, AND SHAREHOLDERS' DEFICIT [1] $ 241,345,034 429,691
Related Party [Member] | Archimedes Tech SPAC Partners II Co    
Current liabilities    
Promissory note - related party   $ 192,033
[1] As of December 31, 2024, included an aggregate of up to 750,000 ordinary shares that were subject to forfeiture depending on the extent to which the underwriters’ over-allotment option was exercised (see Note 5). On February 12, 2025, the Company consummated its Initial Public Offering and sold 23,000,000 Units, including 3,000,000 Units sold pursuant to the full exercise of the underwriters’ option to purchase additional units to cover the over-allotment; as a result, the 750,000 ordinary shares were no longer subject to forfeiture.